In a patient with heart failure who is iron‑deficient but has a normal hemoglobin, should intravenous iron be given and what dosing regimen is recommended?

Intravenous Iron Should Be Administered in Heart Failure Patients with Iron Deficiency and Normal Hemoglobin

Yes, intravenous iron therapy should be given to patients with heart failure and iron deficiency even when hemoglobin is normal, as iron deficiency independently impairs exercise capacity and quality of life regardless of anemia status. 1

Rationale for Treatment

The benefit of IV iron in heart failure extends beyond correction of anemia. Iron deficiency is uniquely associated with reduced exercise capacity, and IV iron repletion improves functional status, symptoms, and quality of life independent of hemoglobin levels 1. The landmark FAIR-HF trial demonstrated significant improvements in NYHA class, 6-minute walk test, and quality of life in both anemic and non-anemic iron-deficient patients 1. More recent evidence shows IV iron reduces the composite endpoint of recurrent heart failure hospitalizations and cardiovascular mortality (RR 0.72,95% CI 0.55-0.89 at 12 months) 2.

Diagnostic Criteria for Iron Deficiency

Iron deficiency in heart failure is defined as 1:

• Ferritin <100 μg/L, OR
• Ferritin 100-299 μg/L with transferrin saturation (TSAT) <20%

Both ferritin and TSAT must be measured simultaneously and evaluated together 1. Do not rely on mean corpuscular volume, MCH, or serum iron alone as these are unreliable markers in heart failure 1.

Patient Selection Criteria

Indications for IV iron therapy 1:

• Symptomatic chronic heart failure with LVEF ≤45% (or <50% per some guidelines) 1
• NYHA class II-IV 1
• Iron deficiency as defined above
• Treatment benefit occurs regardless of anemia status 1

Contraindications 1:

• Hemoglobin >15 g/dL (efficacy and safety not established) 1
• Hypersensitivity to IV iron products 1
• Anemia not attributed to iron deficiency 1
• Evidence of iron overload 1
• Ongoing bacteremia 1

Use with caution 1:

• Acute or chronic infection 1
• History of severe asthma, eczema, or atopic allergies 1
• Immune/inflammatory conditions (SLE, rheumatoid arthritis) 1

Recommended Dosing Regimen

Ferric Carboxymaltose (FCM) - Preferred Agent

FCM is the most extensively studied IV iron preparation in heart failure 1 and is recommended by the 2022 AHA/ACC/HFSA and 2016 ESC guidelines 1.

Dosing calculation based on body weight and hemoglobin 1:

Hemoglobin (g/dL)	<35 kg	35-70 kg	≥70 kg
<10	500 mg	1500 mg	2000 mg
10 to <14	500 mg	1000 mg	1500 mg
14-15	500 mg	500 mg	500 mg

Administration details 1:

• Maximum dose: 1000 mg iron (20 mL FCM) per week 1
• Can be given as undiluted slow IV bolus (100 mg/min, or 15 minutes for 1000 mg dose) 1
• Alternatively, can be given as IV infusion (diluted in maximum 250 mL normal saline for 1000 mg dose, minimum 15 minutes infusion time) 1
• Do not over-dilute as this affects drug stability 1
• Observe patient for at least 30 minutes post-injection for adverse effects 1

Why Oral Iron Is Not Recommended

Oral iron is ineffective in heart failure patients 1. The IRONOUT HF trial showed oral iron polysaccharide failed to improve exercise capacity or heart failure symptoms despite high doses 1. Poor gastrointestinal absorption and inadequate iron store repletion make oral iron unsuitable for this population 1. Gastrointestinal side effects occur in up to 60% of patients, and treatment duration may exceed 6 months without achieving adequate repletion 1.

Monitoring Protocol

Initial reassessment 1:

• Re-evaluate iron status (ferritin and TSAT) at 3 months after initial correction dose 1
• Avoid early re-evaluation within 4 weeks as ferritin levels increase markedly post-IV iron and cannot accurately reflect iron status during this period 1

Ongoing monitoring 1:

• Check iron parameters 1-2 times per year as part of routine follow-up 1
• Re-evaluate if symptoms persist despite optimal heart failure medications 1
• Re-evaluate if hemoglobin decreases 1
• Provide additional iron repletion as needed based on repeat testing 1

If no response or hemoglobin decreases, investigate for occult blood loss and other underlying causes 1.

Clinical Outcomes

Quality of life and functional capacity improvements 1:

• Significant improvements in NYHA class 1
• Enhanced 6-minute walk distance 1
• Better patient-reported quality of life 1
• Benefits occur independent of anemia status 1

Hard clinical endpoints 1, 2:

• Reduced recurrent heart failure hospitalizations (RR 0.78,95% CI 0.55-0.98) 2
• Trend toward lower cardiovascular mortality (HR 0.87,95% CI 0.73-1.04) 2
• The AFFIRM-AHF trial showed decreased heart failure hospitalization with IV ferric carboxymaltose (RR 0.74,95% CI 0.58-0.94) 1
• Treatment effects are greatest in the first year when IV iron doses are highest 2

Important Caveats

• Limited evidence in HFpEF (LVEF ≥50%) and HFmrEF (LVEF 40-49%) 1
• IV iron can be administered in hospital or community settings where staff are trained to manage hypersensitivity reactions 1
• Hypersensitivity reactions occur at low frequency (≥0.1% to <1.0%) 1
• Common minor side effects include dizziness, headache, hypertension, hypophosphatemia, injection-site reactions, and nausea 1
• Ensure proper IV line placement to avoid skin staining from extravasation 1